Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CKPT Checkpoint Therapeutics	$4.26 +0.7%	$4.08	$1.75 ▼ $4.50	$370.71M	1.18	1.38 million shs	8.63 million shs
ERAS Erasca	$1.45 +31.8%	$1.29	$1.01 ▼ $3.45	$410.77M	1.12	1.75 million shs	3.93 million shs
FULC Fulcrum Therapeutics	$7.07 +2.5%	$4.24	$2.32 ▼ $10.13	$381.63M	2.29	969,517 shs	752,690 shs
IMUX Immunic	$0.68 -25.3%	$1.02	$0.56 ▼ $2.11	$65.17M	1.73	992,591 shs	9.22 million shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CKPT Checkpoint Therapeutics	+0.95%	+1.20%	+2.92%	+56.09%	+136.31%
ERAS Erasca	+1.85%	-9.84%	-21.43%	-14.73%	-56.35%
FULC Fulcrum Therapeutics	+8.66%	+10.40%	+93.28%	+104.75%	-10.85%
IMUX Immunic	+2.27%	-1.07%	-18.73%	-18.73%	-27.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CKPT Checkpoint Therapeutics	2.431 of 5 stars	1.2	4.0	4.2	2.7	0.8	0.0
ERAS Erasca	3.5991 of 5 stars	4.5	1.0	0.0	3.5	2.5	1.3
FULC Fulcrum Therapeutics	0.5624 of 5 stars	1.3	1.0	0.0	2.7	2.5	0.0
IMUX Immunic	2.8543 of 5 stars	3.6	4.0	0.0	3.1	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CKPT Checkpoint Therapeutics	2.33	Hold	$4.33	1.84% Upside
ERAS Erasca	3.00	Buy	$4.57	218.57% Upside
FULC Fulcrum Therapeutics	2.50	Moderate Buy	$6.29	-10.89% Downside
IMUX Immunic	3.25	Buy	$11.60	1,578.73% Upside

Current Analyst Ratings Breakdown

Latest IMUX, CKPT, FULC, and ERAS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	FULC Fulcrum Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$6.00 ➝ $9.00
5/29/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $10.00
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $12.00
5/23/2025	IMUX Immunic	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $5.00
5/16/2025	IMUX Immunic	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/15/2025	FULC Fulcrum Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$10.00
5/14/2025	ERAS Erasca	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$3.00
5/1/2025	IMUX Immunic	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/30/2025	ERAS Erasca	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
4/30/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CKPT Checkpoint Therapeutics	$41K	9,030.98	N/A	N/A	($0.47) per share	-9.05
ERAS Erasca	N/A	N/A	N/A	N/A	$2.10 per share	N/A
FULC Fulcrum Therapeutics	$80M	4.76	N/A	N/A	$3.80 per share	1.86
IMUX Immunic	N/A	N/A	N/A	N/A	$0.64 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CKPT Checkpoint Therapeutics	-$51.85M	-$1.29	N/A	∞	N/A	N/A	N/A	-659.07%	8/11/2025 (Estimated)
ERAS Erasca	-$125.04M	-$0.62	N/A	N/A	N/A	N/A	-42.26%	-34.97%	8/11/2025 (Estimated)
FULC Fulcrum Therapeutics	-$97.33M	-$0.07	N/A	N/A	N/A	N/A	-7.31%	-6.74%	7/30/2025 (Estimated)
IMUX Immunic	-$93.61M	-$1.23	N/A	N/A	N/A	N/A	-169.55%	-118.96%	8/14/2025 (Estimated)

Latest IMUX, CKPT, FULC, and ERAS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	IMUX Immunic	-$0.25	-$0.25	N/A	-$0.25	N/A	N/A
5/13/2025	Q1 2025	CKPT Checkpoint Therapeutics	-$0.10	-$0.19	-$0.09	-$0.19	$4.53 million	N/A
5/13/2025	Q1 2025	ERAS Erasca	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A
5/1/2025	Q1 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A
3/28/2025	Q4 2024	CKPT Checkpoint Therapeutics	-$0.22	-$0.69	-$0.47	-$0.69	N/A	$0.04 million
3/20/2025	Q4 2024	ERAS Erasca	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CKPT Checkpoint Therapeutics	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CKPT Checkpoint Therapeutics	N/A	0.29	0.29
ERAS Erasca	N/A	11.00	11.00
FULC Fulcrum Therapeutics	N/A	18.44	18.44
IMUX Immunic	N/A	2.71	2.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CKPT Checkpoint Therapeutics	22.00%
ERAS Erasca	67.78%
FULC Fulcrum Therapeutics	89.83%
IMUX Immunic	51.82%

Insider Ownership

Company	Insider Ownership
CKPT Checkpoint Therapeutics	2.10%
ERAS Erasca	14.40%
FULC Fulcrum Therapeutics	7.00%
IMUX Immunic	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CKPT Checkpoint Therapeutics	10	87.02 million	47.81 million	Optionable
ERAS Erasca	120	283.29 million	221.94 million	Optionable
FULC Fulcrum Therapeutics	100	53.98 million	51.73 million	Optionable
IMUX Immunic	70	95.82 million	87.38 million	Optionable

IMUX, CKPT, FULC, and ERAS Headlines

Recent News About These Companies

Immunic unveils pricing of $65M underwritten public offering

May 29 at 8:22 AM | proactiveinvestors.com

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

May 29 at 7:05 AM | prnewswire.com

Immunic, Inc. Announces Proposed Public Offering

May 28 at 4:02 PM | prnewswire.com

Immunic (NASDAQ:IMUX) Receives Buy Rating from B. Riley

May 25, 2025 | marketbeat.com

Immunic Analyst Ratings and Price Targets | NASDAQ:IMUX | Benzinga

May 24, 2025 | benzinga.com

Janus Henderson Group PLC Cuts Stock Holdings in Immunic, Inc. (NASDAQ:IMUX)

May 23, 2025 | marketbeat.com

Immunic, Inc. (NASDAQ:IMUX) Given Consensus Rating of "Buy" by Analysts

May 22, 2025 | americanbankingnews.com

Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of "Buy" by Analysts

May 19, 2025 | marketbeat.com

Immunic (IMUX) Expected to Announce Quarterly Earnings on Wednesday

May 9, 2025 | marketbeat.com

William Blair Analysts Boost Earnings Estimates for Immunic

May 6, 2025 | marketbeat.com

Leerink Partnrs Has Bullish Estimate for Immunic Q2 Earnings

May 6, 2025 | marketbeat.com

Research Analysts Issue Forecasts for Immunic Q1 Earnings

May 4, 2025 | marketbeat.com

Immunic (NASDAQ:IMUX) Receives "Buy" Rating from HC Wainwright

May 3, 2025 | marketbeat.com

Immunic Reports Positive Data From Phase 2 CALLIPER Study Of Vidofludimus Calcium

May 2, 2025 | nasdaq.com

D. Boral Capital Reiterates "Buy" Rating for Immunic (NASDAQ:IMUX)

May 2, 2025 | marketbeat.com

Immunic to Participate in Scientific and Industry Conferences in May

May 2, 2025 | prnewswire.com

Immunic, Inc. (NASDAQ:IMUX) Shares Sold by Adage Capital Partners GP L.L.C.

May 2, 2025 | marketbeat.com

Immunic Talks Up Disability Gains as Phase II MS Therapy Fails on Primary Endpoint

May 1, 2025 | biospace.com

MS drug shows promise in progressive cases, despite missed trial goal

May 1, 2025 | thepharmaletter.com

Immunic CEO says 'nobody should care at all' about missed primary endpoint in MS study

May 1, 2025 | fiercebiotech.com

Immunic drops after mid-stage trial data for multiple sclerosis drug

May 1, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUX, CKPT, FULC, and ERAS Company Descriptions

Checkpoint Therapeutics NASDAQ:CKPT

$4.26 +0.03 (+0.71%)

Closing price 04:00 PM Eastern

Extended Trading

$4.28 +0.02 (+0.35%)

As of 04:37 PM Eastern

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Erasca NASDAQ:ERAS

$1.45 +0.35 (+31.82%)

Closing price 04:00 PM Eastern

Extended Trading

$1.40 -0.04 (-3.10%)

As of 04:44 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Fulcrum Therapeutics NASDAQ:FULC

$7.07 +0.17 (+2.46%)

Closing price 04:00 PM Eastern

Extended Trading

$7.06 0.00 (-0.07%)

As of 04:04 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Immunic NASDAQ:IMUX

$0.68 -0.23 (-25.28%)

Closing price 04:00 PM Eastern

Extended Trading

$0.68 +0.00 (+0.57%)

As of 04:49 PM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time